We would like to show you a description here but the site won’t allow us. Gabapentin has been administered to several geriatric patients with bipolar disorder and patients with dementia. It has also been reported to be successful in the treatment of a 13-year-old boy with behavioural dyscontrol, a finding that suggested a possible role for gabapentin in the treatment of other behavioural disorders. Chronic Pain in the Elderly Population. Persistent pain (three to six months) is present in 25–50% of older adults, and increases with age. Nursing home patients may have prevalence as high as 45–80%.33 We describe a case where gabapentin was used to treat a patient with mixed Alzheimer's/vascular dementia presenting with severe aggression requiring hospitalization. The case is followed by a systematic review of current literature of the use of these drugs in aggression in patients with dementia. Pharmacodynamics of pregabalin and gabapentin “Dementia comes with lots of behavioral issues, from changes in sleep and depression to apathy and withdrawal, and providers, patients and caregivers may naturally seek to address these through medications,” says Donovan Maust, M.D., M.S., the lead author of the study and an associate professor of psychiatry at Michigan Medicine, U-M’s The evidence of gabapentin and dementia is mixed, with two studies looking at hundreds of thousands of people and coming to completely different conclusions. The HR (95% CI) of dementia for gabapentin or pregabalin exposure was 1.45 (1.36–1.55) compared to non-exposure group, after adjustment for diabetes mellitus, hypertension, stroke, hyperlipidemia, depression, and head injury. The clinic's database was searched to identify patients diagnosed with dementia (all types) and agitation, and treated with either gabapentin or pregabalin between January 2019 and April 2023. Medical records, brain images, and laboratory findings were reviewed retrospectively. Our patient, a 77-year-old Czech woman with incipient vascular dementia, received gabapentin 400mg at bedtime for 6 months and showed convincing improvement. Gabapentin was very effective in treating nocturnal agitation. Keywords: gabapentin, sleep, nocturnal agitation. Preliminary low-grade evidence based on case series and case reviews suggests possible benefit of gabapentin and pregabalin in patients with BPSD in Alzheimer's disease. These benefits cannot be confirmed until well-powered randomized controlled trials are undertaken. Next, it is unclear whether gabapentin is equally efficacious in Alzheimer’s dementia versus concomitant Alzheimer’s and vascular dementia. Additionally, the age difference of 17?years may have also contributed to the 97-year old’s limited response to gabapentin. Also, the first patient received a total gabapentin dose of 300mg Gabapentin use was significantly associated with decline in cognitive and functional status among older adults with initially normal cognition. Further studies are needed to examine the association. The first patient with Alzheimer's Dementia was followed for months while the second patient with mixed dementia patient was only followed for three weeks. Next, it is unclear whether gabapentin is equally efficacious in Alzheimer's dementia versus concomitant Alzheimer's and vascular dementia. Absolute risk was also expressed as the number needed to harm (NNH) (1 / absolute risk difference). This measure indicates how many patients need to receive a high dose of gabapentin to cause harm to one patient who otherwise would not have been harmed if all patients received a low dose gabapentin (a lower number indicating greater harm). low dose gabapentin can be used for treatment of patients with dementia with Lewy bodies. Purpose: To evaluate low dose Gabapentin (GBP) for treatment of disruptive behavioral symptoms in patients with moderate - severe dementia with Lewy bodies. Methods: A case series in a community setting. Eleven The authors describe the use of gabapentin in the treatment of 4 outpatients with dementia-associated agitation. On the basis of clinical case reports and the Overt Agitation Severity Scale, all 4 patients had reduced agitation with gabapentin. Three of 4 patients were successfully titrated to a full dose of 2,400mg/day. These findings suggest a possible role for gabapentin in the behavioral treatment in the other three patients. Patients were on gabapentin treatment at the time of review from 3 to 5 months. All patients tolerated gabapentin well, and all patients had a significant response to it, both in terms of clinically significant responses. It was felt in each case that, if the aggressive behavior had continued, patients These findings suggest a possible role for gabapentin in the behavioral management of patients with dementia. Patients with dementia experience progressive cognitive decline and may manifest a variety of behavioral symptoms. We estimated the yearly prevalence of gabapentin use, both overall and within subgroups defined by cognitive status [normal, mild cognitive impairment, and dementia] and demographics [age and sex] for participants aged 65+. Long-term Gabapentin therapy for chronic pain is not associated with a differential risk of dementia across dosage levels, irrespective of age or gender. Further study into its potential cognitive impacts is essential. 1. Introduction.
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
![]() | ![]() |
![]() | ![]() |
![]() | ![]() |
![]() | ![]() |
![]() | ![]() |
![]() | ![]() |